Miltefosine
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
- Miltefosine no longer needs to be obtained through the CDC.
- See www.impavido.com or call 407-270-7790 for ordering information.
NON-FDA APPROVED USES
- Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
- Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.
- Miltefosine no longer needs to be obtained through the CDC.
- See www.impavido.com or call 407-270-7790 for ordering information.
NON-FDA APPROVED USES
- Treatment of free-living amoeba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
- Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans
There's more to see -- the rest of this entry is available only to subscribers.